Catherine Skari
-
Jan- 2024 -24 JanuaryScientific Literature
Pregnancy Outcomes and Iron Status in β-Thalassemia Major and Intermedia: A Systematic Review and Meta-analysis
Advancements in orally bioavailable iron chelators and MRI methods have improved life expectancy and reproductive potential in Thalassemia Major (TM)…
Read More » -
24 JanuaryScientific Literature
A Cross-Sectional, Multicenter, Disease-Specific, Health-Related Quality of Life study in Greek Transfusion Dependent Thalassemia Patients
The assessment of Health-Related Quality of Life (HRQoL) in Thalassemia offers a holistic approach to the disease and facilitates better…
Read More » -
24 JanuaryScientific Literature
Economic and Clinical Burden of Managing Transfusion-Dependent b-Thalassemia in the United States
Aims To describe clinical complications, treatment use, healthcare resource utilization (HCRU), and costs among patients with transfusion-dependent β-thalassemia (TDT) in…
Read More » -
24 JanuaryScientific Literature
Erythropoiesis in Lower-risk Myelodysplastic Syndromes and Beta Thalassemia
The hematologic disorders myelodysplastic syndromes and beta-thalassemia are characterized by ineffective erythropoiesis and anemia, often managed with regular blood transfusions. Erythropoiesis, the process…
Read More » -
18 JanuaryNews
MYELODYSPLASTIC SYNDROMES | Advantages of Iron Chelation Revealed in Analysis of Low-Risk MDS
A recent groundbreaking study sheds new light on the effectiveness of iron chelation therapy (ICT) for patients suffering from low-risk…
Read More » -
17 JanuaryNews
BREAKING | Vertex and CRISPR’s Gene-editing Therapy Casgevy Receives Early FDA Approval for β-Thalassaemia Treatment
Just one month prior, Casgevy made history as the first CRISPR gene editing therapy to enter the US market when…
Read More » -
16 JanuaryNews
EXCLUSIVE WEBINAR | Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia
📌 Webinar Title: Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia 📌 Date & Time: Friday, February 02, 2024, 15:00…
Read More » -
11 JanuaryNews
Chinese Base Editing Therapy ‘Clinically Cured’ Patient with β-Thalassaemia, Researchers Say
Shanghai-based biotech company CorrectSequence Therapeutics, in collaboration with Guangxi Medical University, has achieved a significant clinical milestone by successfully treating…
Read More » -
8 JanuaryNews
COLD AGGLUTININ DISEASE | ANX1502 Passes Phase 1 Trial, Proving Safe for Healthy Volunteers
Administered orally as a liquid suspension, ANX1502 demonstrated good tolerability, with no serious side effects reported. The drug’s pharmacokinetics also…
Read More » -
2 January
